Deal of the Day — limited-time pharmacy picks!
Brcarib 150mg Tablet

Brcarib 150mg Tablet

Prescription requiredRx Required

Salt Composition: Olaparib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

30 Tablets in Bottle

About The Product

Ovarian Cancer, Breast Cancer

Description

Brcarib 150mg tablet is a first line targeted therapy which is prescribed for ovarian and breast cancer treatment In women. Its active ingredient is Olaparib and belongs to the class of PARP inhibitor.

It helps by blocking the PARP enzyme as it is responsible for the growth of cancer cells in the body. It can prevent the body from further cancer cell multiplication and slow the progression of the disease.

Doctor's must prescribe this medication and determine the appropriate dose and duration based on the patient's condition.

Indication

Ovarian and breast cancer

Common Side Effects

  • Brcarib 150mg tablet can cause side effects, some are mild and severe.
  • The medication side effects also depend on the patient body response to the treatment.
  • If the symptoms persist, kindly discuss with the doctor and manage the side effects effectively: ● Muscle cramps ● Confusion, visual disturbances, seizures, and headache ● Breathlessness ● Swelling of feet ● Changes in heartbeat ● High blood pressure ● Pneumonia ● Loss of appetite ● Sensitivity, tingling and burning sensation of the skin ● Nausea, vomiting, and diarrhea ● Mouth ulcers ● Constipation

Dosage And Duration

  • Brcarib 150mg tablet should be taken orally, do not chew or crush the tablet just take it with the whole glass of water.
  • Avoid skipping the medicine as it can affect the treatment outcomes.
  • Consult the doctor about the correct dosage and duration of the medicine.
  • Never adjust the dose or stop the medication on your own without medical advice.

Mechanism Of Action

Breast and ovarian cancer is generally caused by the mutation caused in the DNA which allow the multiplication of normal cells into cancer cells. Brcarib 150mg tablet contains PARP inhibitor which blocks the pathway of DNA mutation and slow the growth of cancer cells in the body.

The medicine is used as a first line therapy in the treatment of ovarian and breast cancer. It can also be used with other combination of medications, particularly in patients with BRCA mutated or homologous recombination deficient (HRD ) tumors.

Safety Advice

Alcohol
Taking Brcarib 150mg tablet with alcohol may be dangerous to the patient's health but consult the doctor before taking the medication.
Driving
Brcarib 150mg tablet may not cause dizziness or sleepiness but patient may still experience some side effects. It is important to monitor the response of medication and report any unusual symptoms to the doctor.
Pregnancy
Brcarib 150mg tablet is not recommended to pregnant and breastfeeding women as it may affect the fetus or newborn. Take guidance from a healthcare expert to ensure safety and precautions.
Kidney
Kidney patients should take precautions while using Brcarib 150mg tablet as dose adjustment and doctor's prescription is much needed.

Reference

• Bochum, S., Berger, S., & Martens, U. M.

(2018). Olaparib.

Small molecules in oncology, 217-233. • Deeks, E. D.

(2015). Olaparib: first global approval.

Drugs, 75(2), 231-240. • Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S.

M., Masuda, N., ... & Conte, P. (2017).

Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533. • de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., ... & Hussain, M.

(2020). Olaparib for metastatic castration-resistant prostate cancer.

New England Journal of Medicine, 382(22), 2091-2102. • Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., ... & de Bono, J. S.

(2015). DNA-repair defects and olaparib in metastatic prostate cancer.

New England Journal of Medicine, 373(18), 1697-1708.

Certified Content

Written By
Venika Choudhary

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By
Dr. Aditya Sarin

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026